Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) have entered into a strategic manufacturing partnership for biosimilars, the companies announced today. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance and Drug Product manufacturing from its biologics facility in Bangalore, India.
The collaboration combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing capabilities to support Formycon's pipeline of biosimilars for global markets. Dr. Stefan Glombitza, CEO of Formycon, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency."
Neeraj Sharma, Managing Director & CEO of OneSource, commented: "We are delighted to partner with Formycon, one of the world's leading biosimilar developers. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide."
The partnership reflects a shared commitment to advancing global access to biosimilars through sustainable, cost-effective manufacturing. OneSource brings an integrated biologics platform spanning cell line development through commercial fill-finish, with five manufacturing facilities approved by global regulatory authorities including the US FDA and EMA. Formycon has three marketed biosimilars—FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept—and four pipeline candidates including FYB206/pembrolizumab and FYB208/dupilumab.
Formycon's FYB4Growth strategy focuses on geographic diversification, smart portfolio strategy, excellence and innovation, and consistent cost efficiency. The company is strategically expanding into high-growth regions such as MENA, APAC, and Latin America through regional partnerships. More information is available at https://www.formycon.com/ and https://www.fyb4growth.com.
OneSource Specialty Pharma is a pure-play global CDMO focusing on complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies. With over 1,600 professionals and state-of-the-art facilities, it serves global pharmaceutical companies seeking efficient end-to-end solutions. More information is available at www.onesourcecdmo.com.
Biosimilars are successor products to biopharmaceutical drugs whose patents have expired, offering more affordable treatment options. Global sales of biosimilars currently amount to around $21 billion, with analysts projecting a rise to over $74 billion by 2030. This partnership aims to broaden sustainable global access to life-changing biosimilar therapies.
